BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced the granting of stock options and restricted stock units (RSUs) to nine newly-hired employees. The compensation committee approved options to purchase 28,400 shares and RSUs covering 20,025 shares of BioCryst common stock. These grants, made on August 30, 2024, serve as inducements for employment and comply with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $8.69 per share, matching the closing price on the grant date. Both options and RSUs will vest in four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term. These equity incentives are subject to BioCryst's Inducement Equity Incentive Plan and respective agreements.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato l'assegnazione di stock option e unità di azioni ristrette (RSU) a nove nuovi dipendenti. Il comitato per le compensazioni ha approvato opzioni per l'acquisto di 28.400 azioni e RSU che coprono 20.025 azioni di azioni ordinarie di BioCryst. Questi conferimenti, effettuati il 30 agosto 2024, fungono da incentivo all'occupazione e sono conformi alla Regola 5635(c)(4) della Nasdaq.
Le stock option hanno un prezzo di esercizio di $8,69 per azione, corrispondente al prezzo di chiusura nella data di concessione. Sia le opzioni che le RSU matureranno in quattro rate annuali uguali, a partire dal primo anniversario della data di concessione, a condizione di continuare l'impiego. Le stock option hanno un termine di 10 anni. Questi incentivi azionari sono soggetti al Piano di Incentivazione di BioCryst e ai relativi accordi.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha anunciado la concesión de opciones sobre acciones y unidades de acciones restringidas (RSU) a nueve nuevos empleados. El comité de compensación aprobó opciones para comprar 28,400 acciones y RSUs que cubren 20,025 acciones de acciones comunes de BioCryst. Estos otorgamientos, realizados el 30 de agosto de 2024, sirven como incentivos para el empleo y cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones sobre acciones tienen un precio de ejercicio de $8.69 por acción, coincidiendo con el precio de cierre en la fecha de otorgamiento. Tanto las opciones como las RSU se consolidarán en cuatro cuotas anuales iguales, comenzando desde el primer aniversario de la fecha de otorgamiento, condicionado a la continuidad del empleo. Las opciones sobre acciones tienen un plazo de 10 años. Estos incentivos de capital están sujetos al Plan de Incentivos de Capital de BioCryst y a los respectivos acuerdos.
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 9명의 새로 고용된 직원에게 주식 옵션과 제한된 주식 단위(RSU)를 부여했다고 발표했습니다. 보상 위원회는 28,400주를 구매할 수 있는 옵션과 20,025주에 대한 RSU를 승인했습니다. 이러한 제안은 2024년 8월 30일에 이루어졌으며, 고용 유인을 제공하고 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
주식 옵션의 행사가격은 주당 $8.69로, 부여일의 종가와 일치합니다. 옵션과 RSU는 부여일의 1주년부터 시작하여 4회의 동등한 연간 할부로 확정됩니다. 이는 지속적인 고용 조건에 따라 시행됩니다. 주식 옵션은 10년 기간을 갖습니다. 이러한 자기자본 유인책은 BioCryst의 유인 자기자본 유인 계획 및 해당 계약에 따라야 합니다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a annoncé l'octroi d'options d'achat d'actions et d'unités d'actions restreintes (RSU) à neuf nouveaux employés. Le comité de rémunération a approuvé des options pour acheter 28,400 actions et des RSU couvrant 20,025 actions de l'action ordinaire de BioCryst. Ces attributions, faites le 30 août 2024, servent d'incitation à l'emploi et sont conformes à la règle de cotation 5635(c)(4) de Nasdaq.
Les options d'achat d'actions ont un prix d'exercice de 8,69 $ par action, correspondant au prix de clôture à la date d'octroi. Les options et les RSU seront acquises en quatre versements annuels égaux, à partir du premier anniversaire de la date d'octroi, sous condition de maintien de l'emploi. Les options d'achat d'actions ont un délai de 10 ans. Ces incitations en actions sont soumises au Plan d'Incitation des Actions de BioCryst et aux accords respectifs.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat die Gewährung von Aktienoptionen und eingeschränkten Aktieneinheiten (RSUs) an neun neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 28.400 Aktien und RSUs, die 20.025 Aktien des Stammkapitals von BioCryst abdecken. Diese Zuteilungen, die am 30. August 2024 vorgenommen wurden, dienen als Anreiz für die Beschäftigung und entsprechen der Nasdaq-Listungsregel 5635(c)(4).
Die Aktienoptionen haben einen Ausübungspreis von 8,69 $ pro Aktie, was dem Schlusskurs am Tag der Gewährung entspricht. Sowohl die Optionen als auch die RSUs werden in vier gleichen jährlichen Raten fällig, beginnend mit dem einjährigen Jubiläum des Gewährungsdatums, abhängig von der Fortsetzung der Beschäftigung. Die Aktienoptionen haben eine Laufzeit von 10 Jahren. Diese Eigenkapitalanreize unterliegen dem Anreiz-Eigenkapital-Anreizplan von BioCryst und den entsprechenden Vereinbarungen.
- Attraction of new talent with equity incentives
- Alignment of employee interests with company performance through stock options and RSUs
- Potential dilution of existing shareholders' equity
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,025 shares, of BioCryst common stock. The options and RSUs were granted as of August 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
How many shares of BioCryst (BCRX) stock options were granted to new employees on August 30, 2024?
What is the exercise price of the stock options granted by BioCryst (BCRX) on August 30, 2024?
How do the restricted stock units (RSUs) granted by BioCryst (BCRX) vest?
What is the term of the stock options granted by BioCryst (BCRX) on August 30, 2024?
